Carlsmed reported 1Q26 orthopedic sales of $16.1 million, up 58.2% compared to the first quarter of 2025.
The company identified a continued focus on medical education and a growing body of compelling clinical outcome data as the driving forces of its procedure volume expansion.
The first quarter also represented Carlsmed’s first full quarter with the aprevo cervical fusion procedure on the market. With an estimated 370,000 annual cervical fusions in the U.S., the company expects this to be an additional growth lever for the aprevo platform.
“I’m proud to report that we grew our total surgeon user base by more than 60% year-over-year, reflective of the rapid clinical adoption of personalized surgery procedures,” said Carlsmed CEO Mike Cordonnier. “We continue to drive particularly strong engagement from early career and post-fellowship surgeons who are eager to adopt new technology to differentiate their practices and improve outcomes.”
The company expects 2026 sales between $72 million and $77 million, reflecting 48% growth at the midpoint.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
1Q25
1Q24
$ Chg
% Chg
Spine
$16.1
$10.2
$5.9
58.2%
Company Earnings
Amt
% of Sales
Sales
$16.1
Cost of Sales
$3.7
22.9%
Sales and Marketing
$5.2
32.1%
General and Admin
$10.3
63.9%
R & D
$6.2
38.6%
Other
($0.6)
(3.6%)
Net Earnings
($8.7)
(54%)
Carlsmed reported 1Q26 orthopedic sales of $16.1 million, up 58.2% compared to the first quarter of 2025.
The company identified a continued focus on medical education and a growing body of compelling clinical outcome data as the driving forces of its procedure volume expansion.
The first quarter also represented Carlsmed's first full...
Carlsmed reported 1Q26 orthopedic sales of $16.1 million, up 58.2% compared to the first quarter of 2025.
The company identified a continued focus on medical education and a growing body of compelling clinical outcome data as the driving forces of its procedure volume expansion.
The first quarter also represented Carlsmed’s first full quarter with the aprevo cervical fusion procedure on the market. With an estimated 370,000 annual cervical fusions in the U.S., the company expects this to be an additional growth lever for the aprevo platform.
“I’m proud to report that we grew our total surgeon user base by more than 60% year-over-year, reflective of the rapid clinical adoption of personalized surgery procedures,” said Carlsmed CEO Mike Cordonnier. “We continue to drive particularly strong engagement from early career and post-fellowship surgeons who are eager to adopt new technology to differentiate their practices and improve outcomes.”
The company expects 2026 sales between $72 million and $77 million, reflecting 48% growth at the midpoint.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
1Q25
1Q24
$ Chg
% Chg
Spine
$16.1
$10.2
$5.9
58.2%
Company Earnings
Amt
% of Sales
Sales
$16.1
Cost of Sales
$3.7
22.9%
Sales and Marketing
$5.2
32.1%
General and Admin
$10.3
63.9%
R & D
$6.2
38.6%
Other
($0.6)
(3.6%)
Net Earnings
($8.7)
(54%)
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
